Posts

Biomanufacturing after COVID: keeping emergency readiness commercially viable

on

Kodiak stock surges after two eye-drug candidates match Eylea in Phase 3

on

Merck licenses SciBrunch’s preclinical KRAS G12D drug in deal worth up to $2.13B

on

Merck and Daiichi withdraw lung-cancer drug filing after FDA pushback

on

Adicet reports encouraging early lupus CAR-T data as shares fall

on

ctDNA clearance: a promising early signal, not yet a definitive endpoint

on

Nektar wins $90 million jury award in dispute with Eli Lilly

on

Stipple Bio named to Endpoints 11 for its precision-oncology approach

on

FDA approves AbbVie’s once-daily Parkinson’s pill Juvmo

on

Oral SERDs after SERENA-4: narrower bets, not the end of the class

on

CARVYKTI five-year data point to durable remissions in multiple myeloma

on

Genentech signs $1.5B-plus AI bispecific-antibody oncology deal with Earendil

on

FDA approves Merck-Eisai Welireg-Lenvima combination for previously treated advanced kidney cancer

on